3 completed, 1 active not recruiting, 1 terminated. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
Follow BRCA2 Mutation Carrier: new trials by email Literature Review of BRCA2 Mutation Carrier trials Research Report on BRCA2 Mutation Carrier
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors veliparib, capecitabine, oxaliplatin - Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach | Phase 1 | Terminated | National Cancer Institute (NCI) | 16 | 2010-10-01 | 2014-04-02 |
| ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors Diagnostic Laboratory Biomarker Analysis, Gemcitabine Hydrochloride, Pharmacological Study - Adult Solid Neoplasm, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2010-05-01 | 2015-07-02 |
| Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Laboratory Biomarker Analysis, Pharmacological Study, Veliparib - Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 98 | 2009-04-20 | 2018-06-29 |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 107 | 2007-09-01 | 2015-05-22 |
Breast Neoplasms (3) · Fallopian Tube Neoplasms (2) · Hereditary Breast and Ovarian Cancer Syndrome (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Colonic Neoplasms (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1)
Adnexal Diseases (4) · Breast Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Gonadal Disorders (4) · Neoplasms (4) · Neoplasms by Site (4) · Ovarian Diseases (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4)
veliparib (4) · Capecitabine (1) · Carboplatin (1) · Gemcitabine (1) · Oxaliplatin (1) · Paclitaxel (1) · Taxes (1) · capivasertib (1) · olaparib (1) · vistusertib (1)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (1)
United States (5)
Ronald Stoller (1) · Shannon N Westin (1) · Shannon Puhalla (1) · Suresh Ramalingam (1) · William Schelman (1)
P30CA047904 (3), U01CA099168 (3), N01CM00038 (1), P30CA014520 (1), P50CA083639 (1), U01CA062491 (1), U01CA062505 (1), U01CA132194 (1), UM1CA186690 (1), UM1CA186716 (1), UM1CA186717 (1)